Benjamin H. Mullin

Identification of a novel small-molecule modulator targeting SNX10 to inhibit osteoclastic bone resorption

Current antiresorptive therapies reduce bone loss by eliminating osteoclasts or inhibiting their formation. However, these approaches could disrupt osteoclast-osteoblast communication and cause serious complications with long-term usage. There is a need for developing new therapi...